A NOVEL THIRD-GENERATION EGFR TYROSINE KINASE INHIBITOR ABIVERTINIB FOR EGFR T790M-MUTANT NON–SMALL CELL LUNG CANCER: A MULTICENTER PHASE I/II STUDY

Share

Share on facebook
Share on linkedin
Share on twitter
Share on email

In this phase I/II trial, the authors investigated a novel third-generation EGFR tyrosine kinase inhibitor (TKI), abivertinib, in patients with non-small cell lung cancer and harboring the T790M resistance mutation. Abivertinib demonstrated favorable efficacy and a tolerable safety profile in patients. Specifically among the 209 patients evaluated, the objective response rate (ORR) was 52.2% (95% CI: 45.2–59.1) and the disease control ratio (DCR) was 88% (95% CI: 82.9– 92.1). Additionally, the median duration of response (DoR) and progression-free disease (PFS) were 8.5 months and 7.5 months, respectively. As for the median overall survival (OS) of 24.9 months.

While further study of these treatments is needed, abivertinib showed promising efficacy with good safety in this trial.

Download here